Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects.

× No keyword cloud information.

36 in total

1. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.

Authors: Chen-Fang Lin; Li-Jiuan Shen; Fe-Lin Lin Wu; Chyi-Huey Bai; Churn-Shiouh Gau
Journal: Br J Clin Pharmacol Date: 2012-11 Impact factor: 4.335

2. Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play?

Authors: Nuggehally R Srinivas
Journal: Eur J Drug Metab Pharmacokinet Date: 2009 Jul-Sep Impact factor: 2.441

3. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors: Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal: JAMA Date: 2010-10-27 Impact factor: 56.272

8. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?

Authors: Mukesh Singh; Tejaskumar Shah; Sasikanth Adigopula; Janos Molnar; Aziz Ahmed; Sandeep Khosla; Rohit Arora
Journal: Indian Heart J Date: 2012-06-21

Review 9. Applied pharmacogenomics in cardiovascular medicine.

Authors: Peter Weeke; Dan M Roden
Journal: Annu Rev Med Date: 2013-10-02 Impact factor: 13.739

10. Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.

Authors: Renée M Ned Mmsc Phd
Journal: PLoS Curr Date: 2010-09-20

Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects.

1. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.

2. Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play?

3. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Review 4. Antiplatelet drug interactions with proton pump inhibitors.

Review 5. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

6. The P2Y(12) receptor as a target of antithrombotic drugs.

7. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.

8. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?

Review 9. Applied pharmacogenomics in cardiovascular medicine.

10. Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.